Psychomotor Disorders: Clinical Trials

12 trials for Psychomotor Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 not yet recruiting, 2 unknown, 1 terminated. 12 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 112Completed 7, Not yet recruiting 2, Unknown 2, Terminated 1
Phase 25Completed 2, Not yet recruiting 1, Terminated 1, Unknown 1

Follow Psychomotor Disorders: new trials by email Literature Review of Psychomotor Disorders trials Research Report on Psychomotor Disorders

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep
Ferrous Sulfate, Placebo - ADHD, Sleep Problems
Phase 1 / Phase 2Not yet recruitingHugo W. Moser Research Institute at Kennedy Krieger, Inc.702027-03-012026-05-04
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
NRL-1004 2.5 mg, ZYPREXA IM 10mg, NRL-1004 5.0 mg - Healthy Adult Participants
Phase 1Not yet recruitingNeurelis, Inc.242026-10-162026-11-06
Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
Dexmedetomidine Hydrochloride - Hyperactive Delirium, Delirium of Mixed Origin
Phase 1 / Phase 2UnknownBruyère Health Research Institute.502024-01-302025-04-15
Memesto Wearable Device for Persons With Dementia
Memesto - Alzheimer Disease
Phase 1CompletedEdgewater Safety Systems, Inc.92022-08-312024-01-03
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
Dexmedetomidine, Placebo - Opioid Withdrawal
Phase 1 / Phase 2CompletedBioXcel Therapeutics Inc2252020-06-092026-08-11
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
Sublingual film containing Dexmedetomidine, Sublingual Placebo Film - Agitation,Psychomotor, Dementia
Phase 1 / Phase 2CompletedBioXcel Therapeutics Inc1002019-12-272026-08-11
Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film - Agitation, Schizophrenia
Phase 1CompletedBioXcel Therapeutics Inc1352019-05-222026-08-11
ASSIST: Treatment for Childhood Apraxia of Speech
ASSIST - Childhood Apraxia of Speech
Phase 1CompletedTemple University512019-04-182026-05-22
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
Zyprexa IM, Zydis, INP105 - Acute Agitation
Phase 1CompletedImpel Pharmaceuticals382018-08-052018-10-04
Evaluating Anodal tDCS Preceding Aphasia Therapy
transcranial direct current stimulation - Stroke, Aphasia
Phase 1 / Phase 2TerminatedNorthwell Health152014-09-012021-04-05
PiB PET Scanning in Speech and Language Based Dementias
C-11 PiB, F-18 FDG - PPA, Primary Progressive Aphasia
Phase 1CompletedMayo Clinic1682010-03-012015-12-22
Study of Depakote for Behavioral and Psychological Symptoms in Dementia
Depakote - Dementia
Phase 1UnknownHearthstone Alzheimer Care202004-03-012006-08-15

Narrower conditions

Psychomotor Agitation (9)  ·  Apraxias (3)  ·  Dementia (3)  ·  Schizophrenia (3)  ·  Aphasia (2)  ·  Alzheimer Disease (1)  ·  Aphasia, Broca (1)  ·  Aphasia, Primary Progressive (1)  ·  Attention Deficit Disorder with Hyperactivity (1)  ·  Behavior (1)  ·  Behavioral Symptoms (1)  ·  Bipolar Disorder (1)  ·  Communication Disorders (1)  ·  Death (1)  ·  Delirium (1)

Broader conditions

Nervous System Diseases (12)  ·  Neurobehavioral Manifestations (12)  ·  Neurologic Manifestations (12)  ·  Pathological Conditions, Signs and Symptoms (12)  ·  Signs and Symptoms (12)  ·  Mental Disorders (11)  ·  Aberrant Motor Behavior in Dementia (9)  ·  Behavior (9)  ·  Dyskinesias (9)  ·  Behavioral Symptoms (8)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Neurocognitive Disorders (5)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (3)

Interventions

Dexmedetomidine (3)  ·  2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1)  ·  Insemination, Artificial, Heterologous (1)  ·  Olanzapine (1)  ·  Transcranial Direct Current Stimulation (1)  ·  Valproic Acid (1)  ·  ferrous sulfate (1)

Sponsors

BioXcel Therapeutics Inc (3)  ·  Bruyère Health Research Institute. (1)  ·  Edgewater Safety Systems, Inc. (1)  ·  Hearthstone Alzheimer Care (1)  ·  Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1)  ·  Impel Pharmaceuticals (1)  ·  Mayo Clinic (1)  ·  Neurelis, Inc. (1)  ·  Northwell Health (1)  ·  Temple University (1)

Countries

United States (9)  ·  Australia (1)  ·  Canada (1)

Top investigators

BioXcel MM, MD (3)  ·  Alison E Pritchard, PhD (1)  ·  Edwin Maas, Ph.D. (1)  ·  James Downar, MDCM, MSc (1)  ·  Jeffery T. Banker, MS (1)  ·  Keith A Josephs, M.D. MST, MSc (1)  ·  Mark Vanelli, MD (1)  ·  Niquita Tugiono, MD (1)  ·  Stephen B Shrewsbury, MD (1)

Results publications

PMID 32609960, PMID 36280451, PMID 40034447

NIH funding

R01DC017768 (1)